Seavey MM - Search Results

1

Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.

Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A. Shahabi V, et al. Among authors: seavey mm. Cancer Gene Ther. 2011 Jan;18(1):53-62. doi: 10.1038/cgt.2010.48. Epub 2010 Aug 20. Cancer Gene Ther. 2011. PMID: 20725099

2

Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.

Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y. Wood LM, et al. Cancer Immunol Immunother. 2011 Jul;60(7):931-42. doi: 10.1007/s00262-011-1002-x. Epub 2011 Mar 23. Cancer Immunol Immunother. 2011. PMID: 21431419 Free PMC article.

3

Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.

Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Maciag PC, et al. Among authors: seavey mm. Cancer Res. 2008 Oct 1;68(19):8066-75. doi: 10.1158/0008-5472.CAN-08-0287. Cancer Res. 2008. PMID: 18829565 Free PMC article.

4

An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.

Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y. Seavey MM, et al. J Immunol. 2009 May 1;182(9):5537-46. doi: 10.4049/jimmunol.0803742. J Immunol. 2009. PMID: 19380802 Free PMC article.

5

Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Wood LM, Guirnalda PD, Seavey MM, Paterson Y. Wood LM, et al. Among authors: seavey mm. Immunol Res. 2008;42(1-3):233-45. doi: 10.1007/s12026-008-8087-0. Immunol Res. 2008. PMID: 19018479 Free PMC article.

6

A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.

Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, Shahabi V. Seavey MM, et al. Clin Cancer Res. 2009 Feb 1;15(3):924-32. doi: 10.1158/1078-0432.CCR-08-2283. Clin Cancer Res. 2009. PMID: 19188163

7

The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.

Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. Wood LM, et al. Among authors: seavey mm. Cancer Immunol Immunother. 2012 May;61(5):689-700. doi: 10.1007/s00262-011-1129-9. Epub 2011 Nov 6. Cancer Immunol Immunother. 2012. PMID: 22057675 Free PMC article.

8

Estradiol-induced vaginal mucus inhibits antigen penetration and CD8(+) T cell priming in response to intravaginal immunization.

Seavey MM, Mosmann TR. Seavey MM, et al. Vaccine. 2009 Apr 14;27(17):2342-9. doi: 10.1016/j.vaccine.2009.02.025. Epub 2009 Feb 14. Vaccine. 2009. PMID: 19428849 Free PMC article.

9

Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.

Seavey MM, Paterson Y. Seavey MM, et al. Breast Cancer (Dove Med Press). 2009 Oct 5;1:19-30. doi: 10.2147/bctt.s6689. eCollection 2009. Breast Cancer (Dove Med Press). 2009. PMID: 24367160 Free PMC article.

10

Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer.

Seavey MM, Lu LD, Stump KL, Wallace NH, Hockeimer W, O'Kane TM, Ruggeri BA, Dobrzanski P. Seavey MM, et al. Mol Cancer Ther. 2012 Apr;11(4):984-93. doi: 10.1158/1535-7163.MCT-11-0951. Epub 2012 Feb 14. Mol Cancer Ther. 2012. PMID: 22334590

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results